The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News

Ionis Pharma Prices First FDA-approved Treatment for Alexander Disease At $285,000 Per Dose

Ionis Pharmaceuticals said on Friday it would price its newly approved therapy ⁠to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the...

New Migraine Prevention Guidelines Released

Updated migraine prevention guidelines recommend preventive treatment for patients with ≥ 4 migraine days per month and incorporate CGRP-targeted therapies into individualized treatment selection.

Novartis Pauses Trials Of Experimental Cell Therapy After Three Deaths

Novartis said on Tuesday it paused eight clinical trials of an experimental cell therapy, called rap-cel, targeting autoimmune and neurological disorders in late ⁠August,...

Cerebral Palsy Linked to Gaps in Gynecologic Care

Cerebral palsy in women is associated with markedly reduced odds of receiving routine preventive gynecologic care.

Borderline Personality: Evidence Has Evolved. Care Hasn’t

A quiet revolution in borderline personality disorder has exposed a disconnect: Treatment works, recovery is possible, yet outdated assumptions continue to shape clinical care.

New Stroke Rehab Guideline Calls for Earlier, Broader Care

The first update to adult stroke rehabilitation and recovery guidelines in a decade emphasizes early, individualized care addressing physical, cognitive, communication, and mental health needs.

Todays Updates

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Todays Updates

FDA Approves Camizestrant for ESR1-Mutated Breast Cancer

The accelerated approval enables an endocrine therapy switch when the ESR1 resistance mutation is detected, rather than waiting for evidence of disease progression.

Latest News

Ionis Pharmaceuticals said on Friday it would price its newly approved therapy ⁠to treat Alexander disease at $285,000 per dose, a day after the U.S. FDA cleared the...

Updated migraine prevention guidelines recommend preventive treatment for patients with ≥ 4 migraine days per month and incorporate CGRP-targeted therapies into individualized treatment selection.

Novartis said on Tuesday it paused eight clinical trials of an experimental cell therapy, called rap-cel, targeting autoimmune and neurological disorders in late ⁠August,...

Cerebral palsy in women is associated with markedly reduced odds of receiving routine preventive gynecologic care.

A quiet revolution in borderline personality disorder has exposed a disconnect: Treatment works, recovery is possible, yet outdated assumptions continue to shape clinical care.

The first update to adult stroke rehabilitation and recovery guidelines in a decade emphasizes early, individualized care addressing physical, cognitive, communication, and mental health needs.

News All Time

Leptomeningeal Metastases: Early Recognition, Diagnosis, and Multidisciplinary Care

Leptomeningeal Metastases: Early Recognition, Diagnosis, and Multidisciplinary Care

Decoding Leptomeningeal Metastases: Strategies for Early Detection and Accurate Diagnosis

Decoding Leptomeningeal Metastases: Strategies for Early Detection and Accurate Diagnosis

Superagers' Exceptional Memory Can't Be Explained by Genes Alone, Study Finds

Inherited Alzheimer's risk didn't differ between superagers and cognitively average older adults

Diarrhea Bug Outbreak Hits 4 More States; Fauci to Testify; Doc Dies in House Fire

Health news and commentary gathered by MedPage Today staff

Hold Off on JAK Inhibitors in Rheumatoid Arthritis Until After Shingles Vax?

Good things come to those who wait -- and to those who don't wait

FDA Approves Tylenol With Naproxen Combination

First OTC fixed-dose combination product to pair acetaminophen with naproxen sodium

FDA Panel Finds a Peptide It Doesn't Like

Over 2-day meeting, six of seven peptides are recommended for adding to bulk compounding list

Brain Worm Culprit in Woman's Hallucinations, Incoherent Speech

MRI uncovers neurocysticercosis in a 52-year-old woman

First-in-Class Drug for ADHD Wins FDA Approval

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older

FDA Scientists Raise Questions About Duchenne Drug

Agency says deramiocel did not meet phase III trial endpoints, contrary to reported data

Feds Delay Autism Meeting; Wildfire Smoke and Migraine; Mortality and MS

News and commentary from the world of neurology and neuroscience

Sugar Rationing in Early Life Linked to Lower Dementia Risk Decades Later

Long-term study looks at what happened when sugar was scarce

FDA Committee Votes Down Duchenne Drug

Agency staff and drug developer disagree on endpoints

Alzheimer's Paper Retracted; MS Before Epstein-Barr Infection; Brain Aging Map

News and commentary from the world of neurology and neuroscience

Fauci Successor Imminent; CDC Expands Outbreak List; Pesticides Linked to ALS

Health news and commentary gathered by MedPage Today staff

FDA Approves First-in-Class Narcolepsy Drug

Oveporexton treats more than symptoms, restores orexin signaling

Recommended News For You

'Chemo brain' cognitive issues linked to poor lymphatic-system drainage

Many Americans unaware of links between HPV and cancers, poll reveals

Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?

In postmenopausal women with hormone receptor-positive tumors, obesity increases the risk of breast cancer recurrence.

Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.

Assisted Dying Under Scrutiny From Medscape's Readers

Hospitalized Kate Middleton; Sen. Paul Demands That Fauci Go To Prison; COVID Returns to Class.

Recommended Articles For You

Navigating the Evolving Landscape of Oncology Clinical Trials in the Era of Precision Medicine 

Exploring Dyscrasias: Uncovering the Causes and Treatments of Unusual Blood Disorders 

Oncology Drug Trends 2025: FDA Approvals, Immuno-Oncology, and Clinical Trial Insights 

Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

AI Model Has Promise for Predicting Checkpoint Inhibitor Activity in NSCLC

2.

Can Children With Low-Risk Hodgkin Lymphoma Skip Radiation?

3.

Who Bears the Cost of "Forever Chemical" Cleanup?

4.

Disparities in use of MRI to detect prostate cancer: Race and location may influence testing

5.

Timely ‘Nudges’ Help Spur Talks on Patient Care Goals

1.

Paving the Path to Precision: A Review of TAR-200 in the Evolving Bladder Cancer Landscape

2.

IGF2BP1 in Blood Disorders: Therapeutic Potential and Comprehensive Functional Insights

3.

Subchorionic Hematoma: Causes, Symptoms, and Treatment 

4.

Remote Monitoring of Hematologic Recovery Patterns

5.

The Importance of Early Detection in Skin Cancer: Why Regular Skin Exams Matter 

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

4.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

Innovations in Hematology

2.

Thromboprophylaxis In Medical Settings

3.

Common Cancer Myths Debunked

4.

Thromboprophylaxis In Medical Settings- An Update

5.

When Unexplained Bruising May Require Blood Testing

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot